Clinical and Translational Radiation Oncology

Slides:

Advertisements

Similar presentations

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

Advertisements

Volume 75, Issue 1, Pages (January 2012)

Management of independent motion between multiple targets in lung cancer radiation therapy Feng Liu, PhD, An Tai, PhD, Ergun Ahunbay, PhD, Elizabeth.

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.

Trine Grantzau, Mette Skovhus Thomsen, Michael Væth, Jens Overgaard

Preoperative endorectal brachytherapy in the treatment of locally advanced rectal cancer: Rethinking neoadjuvant treatment Matthew C. Biagioli, MD, MS,

PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma Kemp H Kernstine, MD, PhD, William Stanford, MD, Brian F Mullan,

Correlation between urinary dose and delayed radiation cystitis after 78Gy intensity- modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up.

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Improved outcome of treating locally advanced lung cancer with the use of Lattice Radiotherapy (LRT): A case report Beatriz E. Amendola, Naipy C. Perez,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours

Clinical and Translational Radiation Oncology

2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs McDermott Niamh , Meunier Armelle , Wong Simon , Buchete.

Physics and Imaging in Radiation Oncology

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era Ryan S. Youland, Miran L. Blanchard, Roxanna Dronca, Lisa Kottschade,

Physics and Imaging in Radiation Oncology

Clinical and Translational Radiation Oncology

Radiation Therapy for Cutaneous T-Cell Lymphomas

Diffusion-Weighted Magnetic Resonance Imaging for Diagnosing Malignant Pulmonary Nodules/Masses: Comparison with Positron Emission Tomography Takeshi.

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

VMAT radiation-induced nausea and vomiting in adjuvant breast cancer radiotherapy: The incidental effect of low-dose bath exposure G. Lazzari, A. Terlizzi,

Physics and Imaging in Radiation Oncology

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report Lore Helene Braun, Stefan.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT? Robin.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Clinical and Translational Radiation Oncology

Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma Annett Linge, Ricarda Rauschenberg, Sophia Blum,

ORAL SESSIONS Journal of Thoracic Oncology

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Hilly or mountainous surface: a new CT feature to predict the behavior of pure ground glass nodules? Andrea Borghesi, Silvia Michelini, Francesco Bertagna,

Follow up results of a prospective study to evaluate the impact of FDG-PET on CT- based radiotherapy treatment planning for oesophageal cancer Sweet Ping.

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results.

Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung.

Combined morphologic and metabolic pipeline for Positron emission tomography/computed tomography based radiotherapy response evaluation in locally advanced.

Angjelina Protik, Marcel van Herk, Marnix Witte, Jan-Jakob Sonke

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer Katrina Woodford, Vanessa Panettieri, Trieumy Tran Le,

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy)

Physics and Imaging in Radiation Oncology

Rectal volume variations and estimated rectal dose during 8 weeks of image-guided radical 3D conformal external beam radiotherapy for prostate cancer

Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients Line Brøndum, Jesper Grau Eriksen, Brita Singers Sørensen,

Targeting Anemia in Patients with Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Aisling Krishnan, Yat Man Tsang, Adéle Stewart-Lord

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Performance of cardiac output measurement derived from arterial pressure waveform analysis in patients requiring high-dose vasopressor therapy S. Metzelder,

Target definition in radiotherapy of prostate cancer using magnetic resonance imaging only workflow Adalsteinn Gunnlaugsson, Emilia Persson, Christian.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

A Review of First-Line Treatment for Small-cell Lung Cancer

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Clinical and Translational Radiation Oncology Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib Azadeh Abravan, Hanne Astrid Eide, Ingerid Skjei Knudtsen, Ayca Muftuler Løndalen, Åslaug Helland, Eirik Malinen Clinical and Translational Radiation Oncology Volume 4, Pages 57-63 (June 2017) DOI: 10.1016/j.ctro.2017.04.002 Copyright © 2017 The Authors Terms and Conditions

Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10 Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10.1016/j.ctro.2017.04.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 1 A) Dose distribution and CT image at treatment planning for a patient receiving RT and erlotinib. Dose range is 0–30Gy. PET/CT images at: B) pre-, C) mid-, and D) post therapy. SUV range is 0.1–2.5. Only the 18F-FDG uptake within the CT lung window is displayed. Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10.1016/j.ctro.2017.04.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Population based 18F-FDG uptake (in terms of SUV) in the lung versus percentage dose at pre-, mid-, and post-therapy across patients separated into a) RT group and b) RT+erlotinib group. The solid lines correspond to first order linear regressions. Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10.1016/j.ctro.2017.04.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Individual a) SUV0s and b) ΔSUVs resulting from linear regressions on the lung 18F-FDG uptake dose response curves at different sessions. The population-based mean is given by a black triangle. Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10.1016/j.ctro.2017.04.002) Copyright © 2017 The Authors Terms and Conditions

Fig. 4 Correlations between baseline 18F-FDG uptake (SUV0) and serum level for the most robust panel of 8 cytokines associated with inflammatory response. Clinical and Translational Radiation Oncology 2017 4, 57-63DOI: (10.1016/j.ctro.2017.04.002) Copyright © 2017 The Authors Terms and Conditions